Form 4: Adaptimmune Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

Adaptimmune Therapeutics' Chief Medical Officer, Elliot Norry, sold 5,584 American Depositary Shares (ADS) to cover tax obligations related to vested stock options.

Summary

• Elliot Norry, Chief Medical Officer of Adaptimmune Therapeutics, sold 5,584 American Depositary Shares (ADS) on January 17, 2025.
• The sale was executed at a weighted average price of $0.5808 per ADS, with individual transactions ranging from $0.5797 to $0.589.
• This sale was part of a 'Sell to Cover' transaction to satisfy tax withholding obligations and associated sale costs related to vested RSU-style share options.
• The options were granted on January 17, 2023, and have now vested.
• Each ADS represents six ordinary shares of Adaptimmune Therapeutics.
• After the sale, Norry retains 7,510 ADSs from this transaction, and also holds 125,755 ADSs and options covering 8,772,230 ordinary shares.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to stock options. It is neither particularly positive nor negative, but rather a normal part of executive compensation.

Positives

• The sale was a standard 'Sell to Cover' transaction to meet tax obligations, indicating a normal process for vested stock options.
• Norry retains a significant number of ADSs and options, showing continued alignment with the company's success.

Risks

• While the sale is routine, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

This is a standard transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when options vest.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies, particularly in the biotech sector where stock options are a significant part of executive compensation.
• Similar transactions are regularly reported by executives at companies like Gilead Sciences, Amgen, and Biogen, where stock options are a common form of compensation.
• The volume of shares sold is relatively small compared to the total holdings of the executive, which is typical for these types of transactions.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it is a routine transaction.
• The sale does not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Adaptimmune Therapeutics, Elliot Norry, ADS, American Depositary Shares, stock options, insider trading, Form 4, tax obligations, RSU, share sale